Siparadigm, LLC acquired Clinical Laboratory Business of Cancer Genetics, Inc. (NasdaqCM:CGIX) for $0.82 million on July 5, 2019. The cash consideration paid by siParadigm at closing was approximately $0.868 million, which includes approximately $0.045 million for certain equipment plus a $1 million advance payment of the Earn-Out (as defined below), less approximately $0.177 million of certain costs incurred by siParadigm on the Company’s behalf prior to closing. The Earn-Out, to be paid over the 24 months post-closing, is based on fees for all tests performed by siParadigm for the Company’s clinical customers during the 12-month period following the closing. Siparadigm, LLC completed the acquisition of Clinical Laboratory Business of Cancer Genetics, Inc. (NasdaqCM:CGIX) on July 5, 2019.